Nasal ObstructionNCT07323888
Traditional vs. Posterior Nasal Radiofrequency Ablation for Chronic Rhinitis
A study testing Traditional Radiofrequency Ablation of Inferior Turbinates With Posterior Nasal Radiofrequency Ablation and Traditional Radiofrequency Ablation of Inferior Turbinates in people with Nasal Obstruction and Chronic Rhinitis, run by Chien Yu Huang at 1 site in Taiwan.
Trial summary
This study is a prospective, single-center, single-blinded randomized controlled trial designed to compare the clinical effectiveness of traditional radiofrequency ablation of the anterior inferior turbinate alone versus expanded radiofrequency ablation including the middle and posterior portions of the inferior… Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Nasal Obstruction, Chronic Rhinitis, Nonallergic Rhinitis
- What is being tested?
- Traditional Radiofrequency Ablation of Inferior Turbinates With Posterior Nasal Radiofrequency Ablation and Traditional Radiofrequency Ablation of Inferior Turbinates
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteTaiwan
- Study dates
- 1 Mar 2026to 1 May 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age between 18 and 65 years old
- Chronic rhinitis symptoms for at least 6 months that have not responded effectively to medication (should include at least Intranasal corticosteroid (ICS) combined with intermittent use of oral antihistamine and, as needed, combination nasal spray) or where medication has not provided sustained improvement
- Total rTNSS ≥ 4 with Moderate to severe rhinorrhea symptoms (24-hour reflective Total Nasal Symptom Score [rTNSS] rhinorrhea score of 1-3) and mild to severe nasal congestion symptoms (rTNSS nasal congestion score of 1-3)
- All enrolled patients routinely undergo endonasal endoscopic examination, or have had a sinus CT within the past month confirming no significant rhinosinusitis."
Who cannot join
- Obstructive anatomical abnormalities limiting access to posterior nasal passages
- Nasal anatomical changes due to previous sinus or nasal surgery or injury
- Ongoing nasal or sinus infection
- History of severe dry eye, chronic epistaxis, rhinitis medicamentosa, or head and neck radiotherapy
- Self-reported history of bleeding tendency
- Current use of anticoagulants with inability to discontinue
Show all 10Show fewer
- Previous chronic rhinitis surgery
- History of poor wound healing after head, neck, or throat surgery
- Pregnancy/lactation
- Neuromuscular disease preventing supine positioning
Trial locations and contacts
1 site in 1 country.
Taiwan1 site
Chiayi Hospital, Ministry of Health and Welfare (MOHW)
Chiayi City, Taiwan, 600
About this study
Official title: Comparison of Traditional Radiofrequency Ablation of Inferior Turbinates With or Without Posterior Nasal Radiofrequency Ablation: A Randomized Controlled Trial
This study is a prospective, single-center, single-blinded randomized controlled trial designed to compare the clinical effectiveness of traditional radiofrequency ablation of the anterior inferior turbinate alone versus expanded radiofrequency ablation including the middle and posterior portions of the inferior turbinate (posterior nasal region). Patients with chronic rhinitis who remain symptomatic despite at least six months of medical therapy will be randomized in a 2:1 ratio to undergo extended posterior nasal ablation versus traditional anterior treatment. Symptom improvement will be evaluated using rTNSS and other validated questionnaires.
Read the detailed description
Chronic rhinitis is a common condition characterized by persistent nasal obstruction and rhinorrhea, leading to significant impairment in quality of life. Radiofrequency ablation of the inferior turbinate is an established minimally invasive treatment for patients with symptoms refractory to medical therapy. However, symptom control may be suboptimal in some patients, particularly when posterior nasal neural components contribute to disease persistence.
Posterior nasal radiofrequency ablation, which extends treatment to the middle and posterior portions of the inferior turbinate, has been proposed as an adjunctive technique to enhance symptom relief by targeting posterior nasal regions. Evidence comparing traditional anterior inferior turbinate radiofrequency ablation with expanded posterior nasal radiofrequency ablation remains limited.
In this prospective, single-center, randomized controlled trial, eligible patients with chronic rhinitis refractory to at least six months of medical therapy will be randomized in a 2:1 ratio to receive either expanded radiofrequency ablation including the middle and posterior portions of the inferior turbinate or traditional anterior inferior turbinate radiofrequency ablation alone. The primary outcome is the response rate based on improvement in reflective Total Nasal Symptom Score (rTNSS), defined as a ≥30% reduction from baseline at 3 months after the procedure. Secondary outcomes include changes in validated symptom and quality-of-life questionnaires and the incidence of procedure-related complications.
- Conditions
- Nasal Obstruction, Chronic Rhinitis, Nonallergic Rhinitis, Rhinorrhea, Inferior Turbinate Hypertrophy
- Being tested
- Traditional Radiofrequency Ablation of Inferior Turbinates With Posterior Nasal Radiofrequency Ablation, Traditional Radiofrequency Ablation of Inferior Turbinates
- Keywords
- Radiofrequency Ablation, Inferior Turbinate Hypertrophy, Chronic Rhinitis, Nasal Obstruction, Rhinorrhea, Posterior Nasal Nerve, Randomized Controlled Trial, Single-Center Study
- Medical subject headings
- Nasal Obstruction, Rhinorrhea
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Traditional Radiofrequency Ablation of Inferior Turbinates With Posterior Nasal Radiofrequency AblationProcedure or surgery
Intervention:
Radiofrequency Ablation (Olympus Celon Elite ESG-400)
- Local anesthesia with 2% lidocaine
- RF ablation at 15W
- Multiple punctures along anterior, middle, and posterior inferior turbinate (15-20 per side)
- Includes posterior nasal region (superior, medial, inferior aspects)
- No nasal packing required
Post-operative care (3 days):
- Tranexamic acid 250mg 1cap BID x3 days
- Amoxicillin 500mg 1 cap BID x3 days
- Acetaminophen 500mg 1tab BID x3 days
- Levocetirizine 5mg 1tab QD x3 days + PRN x4 days
Traditional Radiofrequency Ablation of Inferior TurbinatesProcedure or surgery
Intervention:
Radiofrequency Ablation (anterior inferior turbinate only)
- Same anesthesia and device
- RF applied only to anterior inferior turbinate (≈2 punctures per side)
- No treatment to middle/posterior inferior turbinate Post-operative care: Same as experimental arm
| Study group | Role | What they receive |
|---|---|---|
| Inferior Turbinate RF with Posterior Nasal RF Ablation | Experimental | Traditional Radiofrequency Ablation of Inferior Turbinates With Posterior Nasal Radiofrequency Ablation Receives: Procedure: Traditional Radiofrequency Ablation of Inferior Turbinates With Posterior Nasal Radiofrequency Ablation |
| Inferior Turbinate RF Ablation | Active comparator | Traditional Radiofrequency Ablation of Inferior Turbinates Receives: Procedure: Traditional Radiofrequency Ablation of Inferior Turbinates |
What is being measured
The primary outcome is the main question the study is designed to answer.
Response rate based on improvement in reflective Total Nasal Symptom Score (rTNSS)
Response is defined as a ≥30% reduction from baseline in the reflective Total Nasal Symptom Score (rTNSS; range 0-12, higher scores indicate worse symptoms).
Measured: 3 months after the procedure
Secondary outcomes (8)
Change in reflective Total Nasal Symptom Score (rTNSS)
Change in reflective Total Nasal Symptom Score (rTNSS; range 0-12, higher scores indicate worse symptoms) from baseline.
Measured: Baseline, 1 week, 1 month, 3 months, 6 months, 9 months, and 12 months after the procedure
Change in Nasal Obstruction Symptom Evaluation (NOSE) score
Change in Nasal Obstruction Symptom Evaluation (NOSE; range 0-20, higher scores indicate worse symptoms) from baseline.
Measured: Baseline, 1 week, 1 month, 3 months, 6 months, 9 months, and 12 months after the procedure
Change in Mini Rhinoconjunctivitis Quality of Life Questionnaire (Mini-RQLQ) score
Change in Mini Rhinoconjunctivitis Quality of Life Questionnaire (Mini-RQLQ; range 0-6, higher scores indicate worse quality of life) from baseline.
Measured: Baseline and 3 months after the procedure
Incidence of intervention-related complications
All self-reported and clinically observed complications related to the intervention.
Measured: From the date of the procedure through 12 months after the procedure
Change in Eustachian Tube Dysfunction Questionnaire-7 (ETDQ-7) score
Change in Eustachian Tube Dysfunction Questionnaire-7 (ETDQ-7; range 7-49, higher scores indicate worse symptoms) from baseline.
Measured: Baseline and 3 months after the procedure
Change in Patulous Eustachian tube handicap inventory-10 (PHI-10) score
Change in Patulous Eustachian tube handicap inventory-10 (PHI-10; range 0-40, higher scores indicate worse symptoms) from baseline.
Measured: Baseline and 3 months after the procedure
Change in Pittsburgh Sleep Quality Index (PSQI) score
Change in Pittsburgh Sleep Quality Index (PSQI; range 0-21, higher scores indicate worse sleep quality) from baseline.
Measured: Baseline and 3 months after the procedure
Change in Epworth Sleepiness Scale (ESS) score
Change in Epworth Sleepiness Scale (ESS; range 0-24, higher scores indicate greater daytime sleepiness) from baseline.
Measured: Baseline and 3 months after the procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jan 2026
- Study start1 Mar 2026
- Primary completion5 Apr 2027 (estimated)
- Study completion1 May 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Nasal ObstructionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chien Yu Huang
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Chien Yu Huang, Chia-Yi Hospital, Ministry of Health and Welfare
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07323888
- Sponsor's protocol ID
- IRB 25-013
- Other IDs
- 25-013
- Status last verified
- May 2026
- First submitted
- 12 Dec 2025
- Last updated
- 13 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared due to patient privacy considerations and institutional data protection policies. Only aggregated results will be presented in publications and reports.
Publications
Stolovitzky JP, Ow RA, Silvers SL, Bikhazi NB, Johnson CD, Takashima M. Effect of Radiofrequency Neurolysis on the Symptoms of Chronic Rhinitis: A Randomized Controlled Trial. OTO Open. 2021 Sep 10;5(3):2473974X211041124. doi: 10.1177/2473974X211041124. eCollection 2021 Jul-Sep.
PubMed 34527852Ehmer D, McDuffie CM, Scurry WC Jr, McIntyre JB, Mehendale NH, Willis JH, Shealy RB, Watkins JP, Kakarlapudi VV. Temperature-Controlled Radiofrequency Neurolysis for the Treatment of Rhinitis. Am J Rhinol Allergy. 2022 Jan;36(1):149-156. doi: 10.1177/19458924211033400. Epub 2021 Aug 12.
PubMed 34382444Lee JT, Abbas GM, Charous DD, Cuevas PDMM, Goktas PDMO, Loftus PA, Nachlas NE, Toskala EM, Watkins JP, Brehmer PDMD. Clinical and Quality of Life Outcomes Following Temperature-Controlled Radiofrequency Neurolysis of the Posterior Nasal Nerve (RhinAer) for Treatment of Chronic Rhinitis. Am J Rhinol Allergy. 2022 Nov;36(6):747-754. doi: 10.1177/19458924221109987. Epub 2022 Jul 11.
PubMed 35818709Takashima M, Stolovitzky JP, Ow RA, Silvers SL, Bikhazi NB, Johnson CD. Temperature-controlled radiofrequency neurolysis for treatment of chronic rhinitis: 12-month outcomes after treatment in a randomized controlled trial. Int Forum Allergy Rhinol. 2023 Feb;13(2):107-115. doi: 10.1002/alr.23047. Epub 2022 Jul 5.
PubMed 35714267
Study at a glance
From the registry record, last updated by the sponsor on 13 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Traditional Radiofrequency Ablation of Inferior Turbinates With or Without Posterior Nasal Radiofrequency Ablation: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07323888
- Acronym / sponsor ID
- IRB 25-013
- Conditions
- Nasal Obstruction, Chronic Rhinitis, Nonallergic Rhinitis, Rhinorrhea, Inferior Turbinate Hypertrophy
- Keywords
- Radiofrequency Ablation, Inferior Turbinate Hypertrophy, Chronic Rhinitis, Nasal Obstruction, Rhinorrhea, Posterior Nasal Nerve, Randomized Controlled Trial, Single-Center Study
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Chien Yu HuangUniversity, hospital or other
- Study start
- 1 Mar 2026 (actual)
- Primary completion
- 5 Apr 2027 (estimated)
- Study completion
- 1 May 2027 (estimated)
- First posted
- 7 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a prospective, single-center, single-blinded randomized controlled trial designed to compare the clinical effectiveness of traditional radiofrequency ablation of the anterior inferior turbinate alone versus expanded radiofrequency ablation including the middle and posterior portions of the inferior turbinate (posterior nasal region). Patients with chronic rhinitis who remain symptomatic despite at least six months of medical therapy will be randomized in a 2:1 ratio to undergo extended posterior nasal ablation versus traditional anterior treatment. Symptom improvement will be evaluated using rTNSS and other validated questionnaires.
Detailed description
Chronic rhinitis is a common condition characterized by persistent nasal obstruction and rhinorrhea, leading to significant impairment in quality of life. Radiofrequency ablation of the inferior turbinate is an established minimally invasive treatment for patients with symptoms refractory to medical therapy. However, symptom control may be suboptimal in some patients, particularly when posterior nasal neural components contribute to disease persistence.
Posterior nasal radiofrequency ablation, which extends treatment to the middle and posterior portions of the inferior turbinate, has been proposed as an adjunctive technique to enhance symptom relief by targeting posterior nasal regions. Evidence comparing traditional anterior inferior turbinate radiofrequency ablation with expanded posterior nasal radiofrequency ablation remains limited.
In this prospective, single-center, randomized controlled trial, eligible patients with chronic rhinitis refractory to at least six months of medical therapy will be randomized in a 2:1 ratio to receive either expanded radiofrequency ablation including the middle and posterior portions of the inferior turbinate or traditional anterior inferior turbinate radiofrequency ablation alone. The primary outcome is the response rate based on improvement in reflective Total Nasal Symptom Score (rTNSS), defined as a ≥30% reduction from baseline at 3 months after the procedure. Secondary outcomes include changes in validated symptom and quality-of-life questionnaires and the incidence of procedure-related complications.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Inferior Turbinate RF with Posterior Nasal RF Ablation | Experimental | Procedure: Traditional Radiofrequency Ablation of Inferior Turbinates With Posterior Nasal Radiofrequency AblationTraditional Radiofrequency Ablation of Inferior Turbinates With Posterior Nasal Radiofrequency Ablation |
| Inferior Turbinate RF Ablation | Active comparator | Procedure: Traditional Radiofrequency Ablation of Inferior TurbinatesTraditional Radiofrequency Ablation of Inferior Turbinates |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Age between 18 and 65 years old
- Chronic rhinitis symptoms for at least 6 months that have not responded effectively to medication (should include at least Intranasal corticosteroid (ICS) combined with intermittent use of oral antihistamine and, as needed, combination nasal spray) or where medication has not provided sustained improvement
- Total rTNSS ≥ 4 with Moderate to severe rhinorrhea symptoms (24-hour reflective Total Nasal Symptom Score [rTNSS] rhinorrhea score of 1-3) and mild to severe nasal congestion symptoms (rTNSS nasal congestion score of 1-3)
- All enrolled patients routinely undergo endonasal endoscopic examination, or have had a sinus CT within the past month confirming no significant rhinosinusitis."
Key exclusion criteria (10 listed)
- Obstructive anatomical abnormalities limiting access to posterior nasal passages
- Nasal anatomical changes due to previous sinus or nasal surgery or injury
- Ongoing nasal or sinus infection
- History of severe dry eye, chronic epistaxis, rhinitis medicamentosa, or head and neck radiotherapy
- Self-reported history of bleeding tendency
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Traditional Radiofrequency Ablation of Inferior Turbinates With Posterior Nasal Radiofrequency AblationIntervention: Radiofrequency Ablation (Olympus Celon Elite ESG-400) * Local anesthesia with 2% lidocaine * RF ablation at 15W * Multiple punctures along anterior, middle, and posterior inferior turbinate (15-20 per side) * Includes posterior nasal region (superior, medial, inferior aspects) * No nasal packing required Post-operative care (3 days): 1. Tranexamic acid 250mg 1cap BID x3 days 2. Amoxicillin 500mg 1 cap BID x3 days 3. Acetaminophen 500mg 1tab BID x3 days 4. Levocetirizine 5mg 1tab QD x3 days + PRN x4 days | Procedure or surgery | Inferior Turbinate RF with Posterior Nasal RF Ablation |
| Traditional Radiofrequency Ablation of Inferior TurbinatesIntervention: Radiofrequency Ablation (anterior inferior turbinate only) * Same anesthesia and device * RF applied only to anterior inferior turbinate (≈2 punctures per side) * No treatment to middle/posterior inferior turbinate Post-operative care: Same as experimental arm | Procedure or surgery | Inferior Turbinate RF Ablation |
Primary outcome
Response rate based on improvement in reflective Total Nasal Symptom Score (rTNSS)
Time frame: 3 months after the procedure
Response is defined as a ≥30% reduction from baseline in the reflective Total Nasal Symptom Score (rTNSS; range 0-12, higher scores indicate worse symptoms).
8 secondary outcomes
Change in reflective Total Nasal Symptom Score (rTNSS)
Time frame: Baseline, 1 week, 1 month, 3 months, 6 months, 9 months, and 12 months after the procedure
Change in Nasal Obstruction Symptom Evaluation (NOSE) score
Time frame: Baseline, 1 week, 1 month, 3 months, 6 months, 9 months, and 12 months after the procedure
Change in Mini Rhinoconjunctivitis Quality of Life Questionnaire (Mini-RQLQ) score
Time frame: Baseline and 3 months after the procedure
Incidence of intervention-related complications
Time frame: From the date of the procedure through 12 months after the procedure
Change in Eustachian Tube Dysfunction Questionnaire-7 (ETDQ-7) score
Time frame: Baseline and 3 months after the procedure
Change in Patulous Eustachian tube handicap inventory-10 (PHI-10) score
Time frame: Baseline and 3 months after the procedure
Change in Pittsburgh Sleep Quality Index (PSQI) score
Time frame: Baseline and 3 months after the procedure
Change in Epworth Sleepiness Scale (ESS) score
Time frame: Baseline and 3 months after the procedure
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 May 2026.
- Background: PubMed 34527852Stolovitzky JP, Ow RA, Silvers SL, Bikhazi NB, Johnson CD, Takashima M. Effect of Radiofrequency Neurolysis on the Symptoms of Chronic Rhinitis: A Randomized Controlled Trial. OTO Open. 2021 Sep 10;5(3):2473974X211041124. doi: 10.1177/2473974X211041124. eCollection 2021 Jul-Sep.
- Background: PubMed 34382444Ehmer D, McDuffie CM, Scurry WC Jr, McIntyre JB, Mehendale NH, Willis JH, Shealy RB, Watkins JP, Kakarlapudi VV. Temperature-Controlled Radiofrequency Neurolysis for the Treatment of Rhinitis. Am J Rhinol Allergy. 2022 Jan;36(1):149-156. doi: 10.1177/19458924211033400. Epub 2021 Aug 12.
- Background: PubMed 35818709Lee JT, Abbas GM, Charous DD, Cuevas PDMM, Goktas PDMO, Loftus PA, Nachlas NE, Toskala EM, Watkins JP, Brehmer PDMD. Clinical and Quality of Life Outcomes Following Temperature-Controlled Radiofrequency Neurolysis of the Posterior Nasal Nerve (RhinAer) for Treatment of Chronic Rhinitis. Am J Rhinol Allergy. 2022 Nov;36(6):747-754. doi: 10.1177/19458924221109987. Epub 2022 Jul 11.
- Background: PubMed 35714267Takashima M, Stolovitzky JP, Ow RA, Silvers SL, Bikhazi NB, Johnson CD. Temperature-controlled radiofrequency neurolysis for treatment of chronic rhinitis: 12-month outcomes after treatment in a randomized controlled trial. Int Forum Allergy Rhinol. 2023 Feb;13(2):107-115. doi: 10.1002/alr.23047. Epub 2022 Jul 5.
- Position Statement: PNN Ablation for the Treatment of Chronic RhinitisLink provided by the sponsor.
- Individual participant dataSharing planned: No. Individual participant data will not be shared due to patient privacy considerations and institutional data protection policies. Only aggregated results will be presented in publications and reports.
Related trials for Nasal Obstruction
Not yet recruiting
Influence of Patient Positioning During Nasal Lavage
Acute Upper Respiratory Tract Infections, Nasal Obstruction
Recruiting
Pharyngeal Mucosal Conditioning to Prevent Postoperative Sore Throat in Septoplasty Patients With Severe Nasal Obstruction
Postoperative Sore Throat, Nasal Obstruction
Active, not recruitingObservational study
A Prospective Study Comparing VivAer to Alternative Surgical Procedures to Treat Nasal Airway Obstruction in Patients With Nasal Valve Dysfunction.
Nasal Airway Obstruction
Recruiting
Measuring Nasal Airway Changes After VivAer Treatment Using AI Analysis
Nasal Airway Obstruction
Recruiting
Post-Market Clinical Study to Evaluate the Safety and Effectiveness of REFLEX ULTRA 45 for Coblation Inferior Turbinate Reduction in China
Nasal Obstruction Due to Inferior Turbinate Hypertrophy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Traditional Radiofrequency Ablation of Inferior Turbinates With Posterior Nasal Radiofrequency Ablation and Traditional Radiofrequency Ablation of Inferior Turbinates in people with Nasal Obstruction and Chronic Rhinitis, run by Chien Yu Huang at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 13 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Response rate based on improvement in reflective Total Nasal Symptom Score (rTNSS) (time frame: 3 months after the procedure). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07323888, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 May 2026.